We place great emphasis on collaboration in our work here at Charnwood Molecular and in our relationships with our clients. In drug discovery projects, our Medicinal Chemistry and Chemical Development teams work closely to offer a seamless transfer from discovery to development phase for your preclinical candidate.
Target ID and Hit-to-Lead
Lead Optimisation Strategy
Chemical Development and Process Research
Scale-up to multi-kg
How we do it.
As a team with wide-ranging and detailed experience gained within pharmaceutical, biotech and fine chemicals companies, we can provide expertise at all stages of the drug discovery pipeline, and provide synthetic and scale-up support to other sectors such as agrochemicals and materials chemistry. Whether you need our services of Target Identification, Hit Identification and Evaluation, Hit-to-Lead, Lead Optimisation, or method development, scale-up and Process Research chemistry, Charnwood Molecular can offer an end-to-end solution.
Changing lives forever.
One example from our portfolio of success stories, demonstrating what can be achieved when innovation, research excellence and collaboration form the basis of CRO-Client relationships is our work with NFlection Therapeutics, which led to the first clinical trial of NFlection’s lead product, NFX-179 Gel, a topically applied therapy for the mitigation of Cutaneous Neurofibromatosis Type-1.
NFlection is working to develop first-in-class soft MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks and immunosuppressant-mediated squamous cell carcinoma – a currently unmet clinical need.
During a highly successful research collaboration, Charnwood Molecular’s Medicinal Chemistry group supported NFlection in the identification of NFX-179, with Charnwood’s Chemical Development team then providing a rapid delivery of the first scale-up batches of API for non-clinical studies and the confirmation of a robust and efficient synthetic route to support clinical manufacture. Working closely with the Nflection team, this led to a seamless technology transfer to a cGMP facility where multi-kilo batches were prepared.
This collaboration demonstrates what can be achieved when innovation, research excellence and collaboration form the basis of CRO-Client relationships, and highlights the advantage of the combined Medicinal Chemistry and Process Research capability here at Charnwood Molecular.
In 2003 Charnwood Molecular relocated to laboratory facilities in Loughborough containing three newly refurbished laboratories, fully equipped for carrying out research chemistry. Our Loughborough site is now home to our Chemical Development and Process Research teams.
In 2012, to serve the growing demand for our medicinal chemistry services, we expanded into additional state-of-the-art research facilities within BioCity, Nottingham, where our company has continued to grow. Here, our experienced medicinal chemists undertake our clients’ Lead Finding and Lead Optimisation programs to rigorous standards.
Meet the team.
Here at Charnwood Molecular, we know that a company’s real strengths lie in the people that it employs. At Charnwood Molecular, our teams bring a wealth of creative experience and proven track records as research scientists within academia, CRO’s, fine chemicals, biotech and from major global pharmaceutical companies.meet the team